Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results

THE WOODLANDS, Texas, May 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2011.  

"Our pipeline of first-in-class drugs continues to make significant progress.  Results from a mechanistic study of a tablet formulation of LX4211 in diabetes patients provided further confirmation of the drug's unique dual mechanism of action, and preparations to initiate a Phase 2b study of LX4211 in the second quarter are on track," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "In addition, we anticipate completing enrollment in the U.S. Phase 2a clinical trial of LX1032 in patients with carcinoid syndrome in the second quarter, with results expected shortly thereafter."

Key Progress in Clinical Pipeline

  • Lexicon reported data from a clinical trial and mechanistic study of a solid oral tablet formulation of LX4211, a dual inhibitor of sodium-glucose cotransporters 1 and 2, showing that LX4211 significantly increased GLP-1 (total and active) and PYY, important mediators of glycemic and appetite control.  The drug also produced rapid and significant improvement in post-prandial glucose (PPG) and fasting plasma glucose (FPG), consistent with results observed in the previously completed Phase 2a study of a liquid formulation of LX4211.  Pharmacokinetic and pharmacodynamic data from the study indicated that the solid oral formulation and the liquid formulation were comparable in key parameters of hormonal release, PPG and FPG.  Lexicon expects to initiate a Phase 2b study of the tablet formulation in the second quarter of this year.
  • Lexicon commenced a Phase 1 study of LX1033, a back-up compound to LX1031 that in vitro studies indicate has the potential to be significantly more potent than LX1031.  LX1031 and LX1033 are each serotonin synthesis inhibitors that act locally in the gastrointestinal tract to reduce serotonin production by inhibiting tryptophan hydroxylase, a key enzyme in the biosynthesis of serotonin.  Lexicon anticipates completing the Phase 1 study of LX1033 in the third quarter of this year.
  • Lexicon expects to initiate a dose-ranging study in the third quarter of this year to explore higher doses of LX2931 in rheumatoid arthritis patients.  Previously reported Phase 2a results of LX2931, an inhibitor of sphingosine-1-phosphate lyase, demonstrated a favorable safety profile at all doses tested and suggested that rheumatoid arthritis patients treated with 150 mg of LX2931 once daily showed improvement in the primary efficacy endpoint of the study, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12.
  • Lexicon continued to enroll carcinoid syndrome patients in a U.S.-based Phase 2a clinical trial of LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels, and anticipates completing enrollment in the second quarter of this year and releasing results shortly thereafter.  Lexicon also continued to enroll carcinoid syndrome patients in a second E.U.-based open-label clinical trial of LX1032.

  • Financial Results Revenues:  Lexicon's revenues for the three months ended March 31, 2011 decreased 64 percent to $0.6 million from $1.6 million for the corresponding period in 2010.  The decrease for the three months ended March 31, 2011 was primarily attributable to reduced revenues under Lexicon's alliance with Taconic Farms.

    Research and Development Expenses:  Research and development expenses for the three months ended March 31, 2011 increased 13 percent to $23.9 million from $21.1 million for the corresponding period in 2010.  The increase was primarily attributable to increased external clinical and preclinical research and development costs and increased severance costs resulting from Lexicon's continued reallocation of resources from earlier-stage research towards its most advanced drug discovery and development programs.  

    Increase in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estimate of the fair value of the liability for the associated base and contingent payments.  Changes in this liability, based on the development of the programs and the time until such payments are expected to be made, are recorded in Lexicon's consolidated statements of operations.  The increase in fair value of the Symphony Icon purchase liability was $1.1 million for the three months ended March 31, 2011.  

    General and Administrative Expenses:  General and administrative expenses for the three months ended March 31, 2011 decreased 14 percent to $4.8 million from $5.5 million for the corresponding period in 2010.  The decrease was primarily attributable to decreased legal and patent fees.Consolidated Net Loss:  Net loss for the three months ended March 31, 2011 was $29.6 million, or $0.09 per share, compared to a net loss of $26.1 million, or $0.13 per share, in the corresponding period in 2010.  For the three months ended March 31, 2011, net loss included non-cash, stock-based compensation expense of $1.5 million, compared to $1.3 million in the corresponding period in 2010.Cash and Investments:  As of March 31, 2011, Lexicon had $188.9 million in cash and investments, as compared to $211.1 million as of December 31, 2010.  

    Lexicon Conference Call:Lexicon management will hold a conference call to discuss financial results for the first quarter of 2011 and program status at 11:00 a.m. Eastern Time on May 3, 2011.  The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international).  The conference ID for all callers is 62216935.  An archived version of the conference call will be available on Lexicon's corporate website at through May 31, 2011.

    About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

    Safe Harbor StatementThis press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX1031, LX1032, LX1033, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedMarch 31,(In thousands, except per share data)20112010(unaudited)Revenues:Collaborative research$  516$  1,641Subscription and license fees80-Total revenues5961,641Operating expenses:Research and development, including stock-based compensationof $839 and $806, respectively23,92121,088Increase in fair value of Symphony Icon, Inc. purchase liability1,058-General and administrative, including stock-based compensationof $633 and $499, respectively4,7535,519Total operating expenses29,73226,607Loss from operations(29,136)(24,966)Gain on investments, net-88Interest income87217Interest expense(607)(727)Other income (expense), net27(682)Consolidated net loss$  (29,629)$  (26,070)Consolidated net loss per common share, basic and diluted$  (0.09)$  (0.13)Shares used in computing consolidated net loss per common share, basic

    and diluted337,527197,239Consolidated Balance Sheet DataAs of March 31,As of December 31,(In thousands)

    20112010(unaudited)Cash and investments$  188,910$  211,111Property and equipment, net51,81553,427Goodwill44,54344,543Other intangible assets53,55753,557Total assets343,408366,884Deferred revenue14,39714,426Current and long-term debt28,19928,483Other long-term liabilities.49,61048,783Accumulated deficit(703,035)(673,406)Total stockholders' equity219,317247,024

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Lexicon to Provide First Quarter 2011 Financial Results
    2. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
    3. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
    5. Lexicon to Report Fourth Quarter and Year End 2010 Financial Results on February 24, 2011
    6. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
    7. Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
    8. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
    9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
    10. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
    11. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
    Post Your Comments:
    (Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
    (Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
    (Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
    Breaking Medicine Technology:
    (Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
    (Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
    (Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
    (Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
    (Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
    Breaking Medicine News(10 mins):